MX381542B - Métodos y composiciones para el tratamiento de la infección por el virus del zika. - Google Patents
Métodos y composiciones para el tratamiento de la infección por el virus del zika.Info
- Publication number
- MX381542B MX381542B MX2018010707A MX2018010707A MX381542B MX 381542 B MX381542 B MX 381542B MX 2018010707 A MX2018010707 A MX 2018010707A MX 2018010707 A MX2018010707 A MX 2018010707A MX 381542 B MX381542 B MX 381542B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- zika virus
- virus infection
- treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 208000001455 Zika Virus Infection Diseases 0.000 title abstract 3
- 208000035332 Zika virus disease Diseases 0.000 title abstract 3
- 208000020329 Zika virus infectious disease Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662304317P | 2016-03-06 | 2016-03-06 | |
| US201662324180P | 2016-04-18 | 2016-04-18 | |
| US201662368111P | 2016-07-28 | 2016-07-28 | |
| US201662370697P | 2016-08-03 | 2016-08-03 | |
| US201662411867P | 2016-10-24 | 2016-10-24 | |
| US201662414466P | 2016-10-28 | 2016-10-28 | |
| US201762462852P | 2017-02-23 | 2017-02-23 | |
| PCT/US2017/020961 WO2017155886A1 (en) | 2016-03-06 | 2017-03-06 | Methods and compositions for treatment of zika virus infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018010707A MX2018010707A (es) | 2019-03-28 |
| MX381542B true MX381542B (es) | 2025-03-04 |
Family
ID=59789791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018010707A MX381542B (es) | 2016-03-06 | 2017-03-06 | Métodos y composiciones para el tratamiento de la infección por el virus del zika. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10512649B2 (enExample) |
| EP (1) | EP3426659A4 (enExample) |
| JP (1) | JP7046015B2 (enExample) |
| AU (1) | AU2017229105B2 (enExample) |
| CA (1) | CA3016588A1 (enExample) |
| MA (1) | MA43812A (enExample) |
| MX (1) | MX381542B (enExample) |
| TW (1) | TWI767903B (enExample) |
| WO (1) | WO2017155886A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7416445B2 (ja) * | 2019-02-18 | 2024-01-17 | 株式会社栄養・病理学研究所 | ブタにおけるｔ細胞の活性化度を評価する方法、ブタにおけるｔ細胞活性化を評価する剤、ブタｔ細胞活性化剤をスクリーニングする方法、ブタの病原体感染を検査する方法、及びハイブリドーマ |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5985848A (en) | 1997-10-14 | 1999-11-16 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of nucleoside metabolism |
| US6228741B1 (en) | 1998-01-13 | 2001-05-08 | Texas Instruments Incorporated | Method for trench isolation of semiconductor devices |
| US7388002B2 (en) | 2001-11-14 | 2008-06-17 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| US7098334B2 (en) | 2002-03-25 | 2006-08-29 | Industrial Research Limited | 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases |
| US7560434B2 (en) | 2004-06-22 | 2009-07-14 | Biocryst Pharmaceuticals, Inc. | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| ES2362805T3 (es) | 2006-09-07 | 2011-07-13 | Industrial Research Limited | Inhibidores aminoacíclicos de nucleósido fosforilasas e hidrolasas. |
| MX2009002707A (es) | 2006-09-11 | 2009-11-26 | Southern Res Inst | Nucleosidos de azoles y su utilizacion como inhibidores de arn y adn polimerasas virales. |
| TW200942243A (en) | 2008-03-05 | 2009-10-16 | Biocryst Pharm Inc | Antiviral therapeutic agents |
| EP2627334B1 (en) | 2010-10-15 | 2015-04-29 | Biocryst Pharmaceuticals, Inc. | Compositions for use in the treatment of viral infections |
-
2017
- 2017-03-06 JP JP2018566196A patent/JP7046015B2/ja active Active
- 2017-03-06 AU AU2017229105A patent/AU2017229105B2/en active Active
- 2017-03-06 TW TW106107257A patent/TWI767903B/zh active
- 2017-03-06 CA CA3016588A patent/CA3016588A1/en active Pending
- 2017-03-06 EP EP17763837.6A patent/EP3426659A4/en active Pending
- 2017-03-06 MX MX2018010707A patent/MX381542B/es unknown
- 2017-03-06 US US16/082,437 patent/US10512649B2/en active Active
- 2017-03-06 MA MA043812A patent/MA43812A/fr unknown
- 2017-03-06 WO PCT/US2017/020961 patent/WO2017155886A1/en not_active Ceased
-
2019
- 2019-11-22 US US16/692,816 patent/US10933066B2/en active Active
-
2021
- 2021-03-01 US US17/188,814 patent/US11975003B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10512649B2 (en) | 2019-12-24 |
| US11975003B2 (en) | 2024-05-07 |
| US20210186976A1 (en) | 2021-06-24 |
| US10933066B2 (en) | 2021-03-02 |
| AU2017229105A1 (en) | 2018-10-11 |
| JP2019507195A (ja) | 2019-03-14 |
| EP3426659A4 (en) | 2019-12-25 |
| EP3426659A1 (en) | 2019-01-16 |
| WO2017155886A1 (en) | 2017-09-14 |
| US20190083496A1 (en) | 2019-03-21 |
| TW201731515A (zh) | 2017-09-16 |
| MA43812A (fr) | 2018-11-28 |
| CA3016588A1 (en) | 2017-09-14 |
| TWI767903B (zh) | 2022-06-21 |
| AU2017229105B2 (en) | 2021-08-12 |
| US20200085830A1 (en) | 2020-03-19 |
| JP7046015B2 (ja) | 2022-04-01 |
| MX2018010707A (es) | 2019-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023013140A (es) | Vacunas contra el virus de la hepatitis b. | |
| EA201890425A1 (ru) | Противовирусные фосфодиамидные сложноэфирные бета-аминокислотные соединения | |
| MX391850B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| EA201792069A1 (ru) | Производные азокана и азонана и способы лечения инфекций гепатита в | |
| DOP2017000137A (es) | Benzamidas sustituidas con 1,3tiazol2ilo. | |
| EA201691845A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
| BR112018008601A2 (pt) | composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer | |
| EA202090098A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
| UY36340A (es) | Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue | |
| CO2018008421A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CO2018009563A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| CL2017001822A1 (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue | |
| MX354123B (es) | Composición antiséptica oral para tratamiento de mucositis oral. | |
| MX389999B (es) | Estabilizadores de mastocitos para el tratamiento de hipercitoquinemia e infeccion viral | |
| BR112016012599A2 (pt) | composição, e, método para tratamento ou prevenção de uma infecção por staphylococcus aureus | |
| NZ764310A (en) | Antibacterial compounds | |
| JOP20200004A1 (ar) | تركيبات طويلة المفعول | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| EA201791432A1 (ru) | Композиции на основе пролекарства монометилфумарата | |
| BR112017003663A2 (pt) | composto, composição, e, método para tratamento de infecção por hiv. | |
| MX2017004318A (es) | Composiciones y metodos para el tratamiento y profilaxis de infecciones del sitio quirurgico. | |
| MX388592B (es) | Compuestos y metodos terapeuticos. | |
| MX389692B (es) | Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc. | |
| MX381542B (es) | Métodos y composiciones para el tratamiento de la infección por el virus del zika. | |
| MX2021006654A (es) | Uso de extracto de cocculus hirsutus para tratar dengue. |